|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neville BW and Day TA: Oral cancer and
precancerous lesions. CA Cancer J Clin. 52:195–215. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marta GN, Riera R, Bossi P, Zhong LP,
Licitra L, Macedo CR, de Castro Junior G, Carvalho AL, William WN
Jr and Kowalski LP: Induction chemotherapy prior to surgery with or
without postoperative radiotherapy for oral cavity cancer patients:
Systematic review and meta-analysis. Eur J Cancer. 51:2596–2603.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Javed F and Warnakulasuriya S: Is there a
relationship between periodontal disease and oral cancer? A
systematic review of currently available evidence. Crit Rev Oncol
Hematol. 97:197–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jain S and Darveau RP: Contribution of
Porphyromonas gingivalis lipopolysaccharide to periodontitis.
Periodontol 2000. 54:53–70. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang H, Wang B, Wang T, Xu L, He C, Wen H,
Yan J, Su H and Zhu X: Toll-like receptor 4 prompts human breast
cancer cells invasiveness via lipopolysaccharide stimulation and is
overexpressed in patients with lymph node metastasis. PLoS One.
9:e1099802014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He Z, Deng R, Huang X, Ni Y, Yang X, Wang
Z and Hu Q: Lipopolysaccharide enhances OSCC migration by promoting
epithelial-mesenchymal transition. J Oral Pathol Med. 44:685–692.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu CH, Chang SH, Narko K, Trifan OC, Wu
MT, Smith E, Haudenschild C, Lane TF and Hla T: Overexpression of
cyclooxygenase-2 is sufficient to induce tumorigenesis in
transgenic mice. J Biol Chem. 276:18563–18569. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kojima M, Morisaki T, Izuhara K, Uchiyama
A, Matsunari Y, Katano M and Tanaka M: Lipopolysaccharide increases
cyclo-oxygenase-2 expression in a colon carcinoma cell line through
nuclear factor-kappa B activation. Oncogene. 19:1225–1231. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gallo O, Franchi A, Magnelli L, Sardi I,
Vannacci A, Boddi V, Chiarugi V and Masini E: Cyclooxygenase-2
pathway correlates with VEGF expression in head and neck cancer.
Implications for tumor angiogenesis and metastasis. Neoplasia.
3:53–61. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chan G, Boyle JO, Yang EK, Zhang F, Sacks
PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, et al:
Cyclooxygenase-2 expression is up-regulated in squamous cell
carcinoma of the head and neck. Cancer Res. 59:991–994.
1999.PubMed/NCBI
|
|
12
|
Gallo O, Masini E, Bianchi B, Bruschini L,
Paglierani M and Franchi A: Prognostic significance of
cyclooxygenase-2 pathway and angiogenesis in head and neck squamous
cell carcinoma. Hum Pathol. 33:708–714. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shin DM, Zhang H, Saba NF, Chen AY,
Nannapaneni S, Amin AR, Müller S, Lewis M, Sica G, Kono S, et al:
Chemoprevention of head and neck cancer by simultaneous blocking of
epidermal growth factor receptor and cyclooxygenase-2 signaling
pathways: Preclinical and clinical studies. Clin Cancer Res.
19:1244–1256. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiang SL, Velmurugan BK, Chung C, Lin SH,
Wang ZH, Hua CH, Tsai MH, Kuo TM, Yeh KT, Chang PY, et al:
Preventive effect of celecoxib use against cancer progression and
occurrence of oral squamous cell carcinoma. Sci Rep. 7:62352017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu XF, Xie CG, Wang XP, Liu J, Yu YC, Hu
HL and Guo CY: Selective inhibition of cyclooxygenase-2 suppresses
the growth of pancreatic cancer cells in vitro and in vivo. Tohoku
J Exp Med. 215:149–157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoshida H, Yoshimura H, Matsuda S, Ryoke
T, Kiyoshima T, Kobayashi M and Sano K: Effects of peritumoral
bevacizumab injection against oral squamous cell carcinoma in a
nude mouse xenograft model: A preliminary study. Oncol Lett.
15:8627–8634. 2018.PubMed/NCBI
|
|
17
|
National Research Council, . Guide for the
Care and Use of Laboratory Animals8th. The National Academies
Press; Washington, DC: 2011
|
|
18
|
Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh
SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ and Lee JO: Crystal
structure of the TLR4-MD-2 complex with bound endotoxin antagonist
Eritoran. Cell. 130:906–917. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu YC, Yeh WC and Ohashi PS: LPS/TLR4
signal transduction pathway. Cytokine. 42:145–151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Abrahão AC, Giudice FS, Sperandio FF and
Pinto Junior Ddos S: Effects of celecoxib treatment over the AKT
pathway in head and neck squamous cell carcinoma. J Oral Pathol
Med. 42:793–798. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kwak YE, Jeon NK, Kim J and Lee EJ: The
cyclooxygenase-2 selective inhibitor celecoxib suppresses
proliferation and invasiveness in the human oral squamous
carcinoma. Ann N Y Acad Sci. 1095:99–112. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li WZ, Wang XY, Li ZG, Zhang JH and Ding
YQ: Celecoxib enhances the inhibitory effect of cisplatin on
Tca8113 cells in human tongue squamous cell carcinoma in vivo and
in vitro. J Oral Pathol Med. 39:579–584. 2010.PubMed/NCBI
|
|
23
|
Grösch S, Tegeder I, Niederberger E,
Bräutigam L and Geisslinger G: COX-2 independent induction of cell
cycle arrest and apoptosis in colon cancer cells by the selective
COX-2 inhibitor celecoxib. FASEB J. 15:2742–2744. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Patil VM, Noronha V, Joshi A, Muddu VK,
Dhumal S, Bhosale B, Arya S, Juvekar S, Banavali S, D'Cruz A, et
al: A prospective randomized phase II study comparing metronomic
chemotherapy with chemotherapy (single agent cisplatin), in
patients with metastatic, relapsed or inoperable squamous cell
carcinoma of head and neck. Oral Oncol. 51:279–286. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Argiris A, Li Y, Murphy BA, Langer CJ and
Forastiere AA: Outcome of elderly patients with recurrent or
metastatic head and neck cancer treated with cisplatin-based
chemotherapy. J Clin Oncol. 22:262–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kawano S, Zheng Y, Oobu K, Matsubara R,
Goto Y, Chikui T, Yoshitake T, Kiyoshima T, Jinno T, Maruse Y, et
al: Clinicopathological evaluation of pre-operative
chemoradiotherapy with S-1 as a treatment for locally advanced oral
squamous cell carcinoma. Oncol Lett. 11:3369–3376. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gartel AL and Tyner AL: The role of the
cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer
Ther. 1:639–649. 2002.PubMed/NCBI
|
|
28
|
Lai FB, Liu WT, Jing YY, Yu GF, Han ZP,
Yang X, Zeng JX, Zhang HJ, Shi RY, Li XY, et al: Lipopolysaccharide
supports maintaining the stemness of CD133(+) hepatoma cells
through activation of the NF-κB/HIF-1α pathway. Cancer Lett.
378:131–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li S, Xu X, Jiang M, Bi Y, Xu J and Han M:
Lipopolysaccharide induces inflammation and facilitates lung
metastasis in a breast cancer model via the prostaglandin E2-EP2
pathway. Mol Med Rep. 11:4454–4462. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xue WP, Bai SM, Luo M, Bi ZF, Liu YM and
Wu SK: Phase I clinical trial of nasopharyngeal radiotherapy and
concurrent celecoxib for patients with locoregionally advanced
nasopharyngeal carcinoma. Oral Oncol. 47:753–757. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cerchietti LC, Bonomi MR, Navigante AH,
Castro MA, Cabalar ME and Roth BM: Phase I/II study of selective
cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in
patients with unresectable brain metastases. J Neurooncol.
71:73–81. 2005. View Article : Google Scholar : PubMed/NCBI
|
